Quality of sleep

The optimal amount, or quantity of sleep varies from individual to individual. However, there is poor correlation between quantity of sleep, as measured by e.g. electrodes in sleep labs, and quality of sleep, as perceived by the patient.

In contrast to other sleep drugs, quality of sleep, as evaluated by validated questionnaires, has been the primary endpoint when developing Circadin. By doing this the patient is in focus: it is the personal experience of the refreshing outcome of their sleep, which is prioritised.

Quality of life

Circadin is fulfilling the unmet needs of insomniacs in good sleep and improves quality of life.

Circadin - Sleep well, Live well

Want to know more about Circadin?

Circadin, prolonged-release melatonin, is a new sleep medication and first in a new class of melatonin agents approved for use in the European Union (EU).

Because of its novel formulation, Circadin mimics the natural melatonin profile by releasing melatonin gradually over 8-10 hours. This results in the re-setting of natural circadian rhythms and the encouragement of natural, restorative sleep.

Circadin is the first sleep agent to demonstrate improvements in quality of life.

The regulatory approval of Circadin represents a new therapeutic principle in insomnia therapy.

Safety

Circadin works via the natural sleep pathway and exhibits no rebound and withdrawal effects - its side effect profile is benign and shows no sign of dependency.